O papel do dolutegravir na terapia antiretroviral
DOI:
https://doi.org/10.34019/1982-8047.2018.v44.13945Palavras-chave:
HIV, Terapia Antirretroviral de Alta Atividade, Síndrome de Imunodeficiência Adquirida, Carga Viral, DolutegravirResumo
Os inibidores da integrase são a mais nova classe de antirretroviral aprovada, que agem impedindo a incorporação do DNA do HIV no genoma do linfócito T CD4+ (LTCD4+) do hospedeiro, limitando a propagação do vírus. O Dolutegravir e o inibidor da integrase mais moderno e como os demais inibidores apresenta de alta performance, boa tolerância; alta barreira genética para mutações de resistência, além de apresentar eficácia em pacientes já submetidos a tratamento antirretroviral anterior. Neste contexto o presente estudo trata-se de um estudo de revisão bibliográfica realizada de janeiro a junho de 2018, de artigos científicos de artigos científicos que abordam aspectos exclusivos do dolutegravir na terapia antirretroviral em comparação com outros esquemas terapêuticos. Concluindo que o tratamento com dolutegravir apresenta como principais vantagens à rápida supressão virológica; boa tolerância e alta barreira genética para mutações de resistência.
Downloads
Referências
BOSWELL, R.; FOISY, M. M.; HUGHES, C. A. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review. Annals of Pharmacotherapy, v. 52, n. 7, p. 681-689, jul. 2018.
CAHN, P. et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. Journal of the International AIDS Society, v. 20, n. 1, p. 21678, may. 2017.
CASTAGNA, A. et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. The Journal of Infectious Diseases, v. 210, n. 3, p. 354-62, aug. 1 2014.
CID-SILVA, P. et al. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Basic & Clinical Pharmacology & Toxicology, v. 121, n. 5, p. 442-446, nov. 2017.
CUFFE, R. et al. Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir. HIV Clinical Trials, v. 16, n. 5, p. 170-7, oct. 2015.
CURTIS, L. et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clinical Trials, v. 15, n. 5, p. 199-208, sep./oct. 2014.
DESCAMPS, D. et al. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clinical Infectious Diseases, v. 60, n. 10, p. 1521-7, may. 2015
ERON, J. J. et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. The Journal of Infectious Diseases, v. 207, n. 5, p. 740-8, mar. 2013.
FERREIRA, B. E.; OLIVEIRA, I. M.; PANIAGO, A. M. Quality of life of people living with HIV/AIDS and its relationship with CD4+ lymphocytes, viral load and time of diagnosis. Brazilian Journal of Epidemiology, v. 15, n. 1, p. 75-84, mar. 2012.
FERREIRA, D. C.; DA SILVA, G. A. Routes to care--the itineraries of people living with HIV. Revista Ciência & Saúde Coletiva, v. 17, n. 11, p. 3087-98, nov. 2012.
FERRER, P. E. et al. A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes. International Journal of STD & AIDS, v. 29, n. 3, p. 300-305, mar. 2018.
GANDHI, M.; GANDHI, R. T. Single-pill combination regimens for treatment of HIV-1 infection. The New England Journal of Medicine, v. 371, n. 3, p. 248-59, jul. 2014
GRINSZTEJN, B. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, v. 369, n. 9569, p. 1261-1269, apr. 2007.
HAZUDA, D.; IWAMOTO, M.; WENNING, L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annual Review of Pharmacology and Toxicology, v. 49, p. 377-94, 2009.
KANDEL, C. E.; WALMSLEY, S. L. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug, Design, Development and Therapy, v. 9, p. 3547-55, 2015.
KATLAMA, C.; MURPHY, R. Dolutegravir for the treatment of HIV. Expert Opinion on Investigational Drugs, v. 21, n. 4, p. 523-30, Apr 2012.
KOBAYASHI, M. et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrobial Agents and Chemotherapy, v. 55, n. 2, p. 813-21, feb. 2011
LENNOX, J. L. et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet, v. 374, n. 9692, p. 796-806, sep. 5 2009.
MARKOWITZ, M. et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of Acquired Immune Deficiency Syndromes, v. 46, n. 2, p. 125-33, oct. 1 2007.
MESPLEDE, T.; WAINBERG, M. A. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses, v. 6, n. 9, p. 3377-85, aug. 27 2014
MIN, S. et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrobial Agents and Chemotherapy, v. 54, n. 1, p. 254-8, jan. 2010.
MOLINA, J. M. et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. The Lancet HIV, v. 2, n. 4, p. e127-36, apr. 2015
PATEL, P. et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. Journal of Antimicrobial Chemotherapy, v. 66, n. 7, p. 1567-72, jul. 2011
RAFFI, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases, v. 13, n. 11, p. 927-35, nov. 2013
RATHBUN, R. C. et al. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Annals of Pharmacotherapy, v. 48, n. 3, p. 395-403, mar. 2014.
ROJAS, J. et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. Journal of Antimicrobial Chemotherapy, v. 71, n. 7, p. 1975-81, jul. 2016.
SAMJI, H. et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLOS One, v. 8, n. 12, p. e81355, 2013.
SHAH, B. M.; SCHAFER, J. J.; DESIMONE, J. A., JR. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy, v. 34, n. 5, p. 506-20, may. 2014.
SHUBBER, Z. et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLOS Medicine, v. 13, n. 11, p. e1002183, nov. 2016.
SONG, I. et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrobial Agents and Chemotherapy, v. 56, n. 3, p. 1627-9, mar. 2012
STEIGBIGEL, R. T. et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. The New England Journal of Medicine, v. 359, n. 4, p. 339-54, jul. 24 2008.
STELLBRINK, H. J. et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS, v. 27, n. 11, p. 1771-8, jul. 17 2013.
TODD, S. et al. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. International Journal of STD & AIDS, v. 28, n. 11, p. 1074-1081, oct. 2017.
VAN LUNZEN, J. et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet infectious diseases, v. 12, n. 2, p. 111-118, 2012.
WALMSLEY, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. The New England Journal of Medicine, v. 369, n. 19, p. 1807-18, nov. 7 2013.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
